Baohuoside I

Research use only, not for human use.

Baohuoside I is a component of Epimedium koreanum, exhibits anti-inflammatory activity and anti-osteoporosis activities.

Baohuoside I is a component of Epimedium koreanum, exhibits anti-inflammatory activity and anti-osteoporosis activities.

Baohuoside I is an inhibitor of CXCR4, and downregulates CXCR4 expression at 12-25 μM. Baohuoside I (0-25 μM) suppresses NF-κB activation in a dose-dependent manner, suppresses CXCL12 induced the invasion of cervical cancer cells. Baohuoside I also inhibits invasion of breast cancer cells. Baohuoside I inhibits A549 cell viability, with IC50s of 25.1 μM at 24 h, 11.5 μM and 9.6 μM at 48 h and 72 h, respectively. Baohuoside I ((25 μM) suppresses the caspase cascade in A549 cells, elevates ROS levels and activates JNK and p38MAPK signaling cascade. Baohuoside I (3.125, 6.25, 12.5, 25.0 and 50.0 μg/mL) significantly and dose-dependently blocks the growth of esophageal squamous cell carcinoma Eca109 cells, with an IC50 of 4.8 μg/mL at 48 h.

Baohuoside I (25 mg/kg) decreases β-catenin protein levels, cyclin D1 and survivin expression in nude mice.

Icariin-II | Icariside-II

Others

Other Targets

CXCR4

Others-Field

——

113558-15-9

514.52

C27H30O10

>98% (HPLC)

DMSO : ≥ 32 mg/mL 62.19 mM

C[C@H]1[C@H](O)[C@H]([C@H]([C@@H](O1)Oc1c(oc2c(c1=O)c(cc(c2CC=C(C)C)O)O)c1ccc(cc1)OC)O)O

——

(-20℃)

With Ice Pack

≥ 2 years